356 related articles for article (PubMed ID: 26233509)
1. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Genovese MC; Hsia E; Belkowski SM; Chien C; Masterson T; Thurmond RL; Manthey CL; Yan XD; Ge T; Franks C; Greenspan A
J Rheumatol; 2015 Oct; 42(10):1752-60. PubMed ID: 26233509
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
7. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
Taylor PC; Genovese MC; Greenwood M; Ho M; Nasonov E; Oemar B; Stoilov R; Vencovsky J; Weinblatt M
Ann Rheum Dis; 2015 Dec; 74(12):2123-9. PubMed ID: 25074688
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
10. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Huizinga TW; Batalov A; Stoilov R; Lloyd E; Wagner T; Saurigny D; Souberbielle B; Esfandiari E
Arthritis Res Ther; 2017 Mar; 19(1):53. PubMed ID: 28274253
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
Stock TC; Bloom BJ; Wei N; Ishaq S; Park W; Wang X; Gupta P; Mebus CA
J Rheumatol; 2012 Apr; 39(4):720-7. PubMed ID: 22382341
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
15. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Genovese MC; Jarosova K; Cieślak D; Alper J; Kivitz A; Hough DR; Maes P; Pineda L; Chen M; Zaidi F
Arthritis Rheumatol; 2015 Jul; 67(7):1703-10. PubMed ID: 25779750
[TBL] [Abstract][Full Text] [Related]
16. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C
Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159
[TBL] [Abstract][Full Text] [Related]
17. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.
Genovese MC; Yang F; Østergaard M; Kinnman N
Ann Rheum Dis; 2016 Nov; 75(11):1979-1983. PubMed ID: 27084959
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
[TBL] [Abstract][Full Text] [Related]
20. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]